Table 1 Demographic and clinical characteristics of COVID-19 patients
Total (n = 342) | |
|---|---|
Demographic Characteristics | |
Male gender [n (%)] | 259 (75.7) |
Age in years, median (IQR) | 39 (33 − 44) |
Education [n (%)] | |
Low | 6 (1.8) |
Middle | 142 (41.5) |
High | 194 (56.7) |
Working status [n (%)] | |
Actively working | 266 (77.8) |
Not working | 76 (22.2) |
Marital status [n (%)] | |
Married | 166 (48.5) |
Widowed | 28 (8.2) |
Not married | 148 (43.3) |
HIV transmission risk [n (%)] | |
Heterosexual | 158 (46.2) |
Homosexual | 93 (27.2) |
IVDU | 72 (21.1) |
Unknown | 19 (5.6) |
Years of HIV diagnosis [n (%)] | |
Newly diagnosed | 15 (4.4) |
≤ 1 year | 36 (10.5) |
2 − 5 years | 85 (24.9) |
6 − 10 years | 104 (30.4) |
> 10 years | 102 (29.8) |
Clinical characteristics | |
Using ART before COVID-19 [n (%)] | 320 (93.6) |
Recent CD4 [n (%)] | |
< 200 cells/mm3 | 48 (14) |
≥ 200 cells/mm3 | 294 (86) |
HIV viral load [n (%)] | |
Virally suppressed | 17 (5) |
Not virally suppressed | 192 (56.1) |
No data | 133 (38.9) |
ART regimen (n = 320) | |
Anchor drugs [n (%)] | |
Nevirapine | 85 (26.6) |
Efavirenz | 168 (52.5) |
Lopinavir/ritonavir | 45 (14.1) |
Dolutegravir | 22 (6.9) |
Backbone drugs [n (%)] | |
Tenofovir | 203 (63.4) |
Zidovudine | 117 (36.6) |
Opportunistic infection* [n (%)] | 34 (9.9) |
Tuberculosis [n (%)] | 27 (7.9) |
Obesity (BMI ≥ 30) [n (%)] | 27 (7.9) |
Diabetes [n (%)] | 13 (3.8) |
Hypertension [n (%)] | 29 (8.5) |
Chronic kidney disease [n (%)] | 7 (2) |
Cardiovascular disease [n (%)] | 5 (1.5) |
Any comorbidity [n (%)] | 64 (18.7) |